Kraig Biocraft Laboratories, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Kraig Biocraft performed this year. My goal is to turn complex filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Kraig Biocraft uses genetic engineering to create high-performance spider silk. They "program" silkworms to produce a hybrid fiber that blends the strength of spider silk with the reliability of traditional silk. They are currently moving from research to commercial production in Vietnam. They target high-value markets like military gear, medical sutures, and luxury textiles.

2. Financial Health: The "Going Concern" Warning

The most important detail is the "going concern" warning from the company’s auditors. This means there is significant doubt about their ability to stay in business for the next 12 months without raising more money. As of December 31, 2025, they held about $0.45 million in cash. This is not enough to fund operations for the coming year. They are not yet profitable and are burning through cash to pay for research and international operations.

3. The "Zero Revenue" Reality

For the second year in a row, Kraig Biocraft reported $0 in revenue. Despite their plans, they have not yet sold their product commercially. Meanwhile, costs are rising. They spent about $3.37 million in 2025, up roughly 9.4% from $3.08 million in 2024. Most of this went toward $1.8 million in administrative costs, including executive pay and legal fees. Essentially, they spend millions annually to develop a product that has yet to generate a single dollar in sales.

4. Major Wins and Changes

• Production Strategy: They use a "plug and play" model in Vietnam, using existing silk farms to avoid the high cost of building their own factories. However, they struggle with consistency. They recently closed a facility in Lam Dong, Vietnam, due to poor performance and are moving to a smaller, more controlled site.
• The "Safety Net" (SEPA): In early 2025, they signed a $10 million "Standby Equity Purchase Agreement." Think of this as a pre-approved credit line where the company forces an investor to buy shares at a discount. This creates new shares, which reduces your ownership percentage and often pushes the stock price down.
• Intellectual Property: They hold over 10 patents and trademarks, such as Monster Silk® and Dragon Silk™. They also rely on "trade secrets"—proprietary knowledge about genetic sequencing—to keep competitors at bay.

5. The Shareholder "Pie"

The company continues to issue millions of shares to pay consultants, board members, and employees instead of using cash. Because they constantly print new shares to fund operations, the "pie" is sliced into smaller pieces. The total number of shares has grown significantly over the last two years. This means your percentage of ownership shrinks over time.

6. Key Risks

• Dilution: The SEPA agreement and stock-based pay mean a constant supply of new shares hits the market. This "dilution overhang" can keep the stock price depressed.
• Execution Risk: They have yet to prove they can move from a lab to large-scale production. The failure at the Lam Dong facility shows how hard it is to scale biological production in a foreign environment.
• Competition: They compete against well-funded firms like Bolt Threads and Spiber. Kraig is a small player in an industry where technical hurdles are high and the path to profit is unproven.

---

Final Thought for Investors: When looking at a company like Kraig Biocraft, ask yourself if you are comfortable with "venture-style" risk. You are essentially betting on a company that has yet to prove its commercial viability and is currently relying on selling shares to keep the lights on. If you decide to invest, keep a close eye on their ability to generate actual sales revenue—that is the only way they will eventually stop relying on diluting shareholders to survive.